Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873269 | 0.91 | HRH3 (0.43) | HRH3KCNH2POLBHSD17B10ALDH1A1 | |
| SCHEMBL24145052 | 0.77 | TFPI2 (0.42) | POLBSIGMAR1 | |
| SCHEMBL21113009 | 0.76 | OGA (0.35) | HRH3KCNH2 | |
| SCHEMBL24145051 | 0.76 | MEN1 (0.45) | ALDH1A1 | |
| SCHEMBL24145064 | 0.75 | SMN1; SMN2 (0.47) | ALDH1A1 | |
| SCHEMBL24145178 | 0.75 | SMN1; SMN2 (0.42) | POLBALDH1A1 | |
| SCHEMBL21113011 | 0.75 | SMN1; SMN2 (0.43) | SIGMAR1ALDH1A1 | |
| SCHEMBL21112937 | 0.74 | PPP5C (0.38) | HRH3HSD17B10 | |
| SCHEMBL24145067 | 0.73 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL20873258 | 0.73 | CHRM3 (0.38) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | HRH3 3993/4885KCNH2 4649/4885POLB 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.